January 17, 2013 at 17:56 PM EST
Valeant, Celgene, Allergan: Strategists Are Bullish
Valeant Pharmaceuticals (VRX) is the lone leader in IBD's medical sector, but it's not the only health care stock that fund managers and strategists see with bright prospects. Mutual funds are a big reason for run-ups in many stocks in the sector. The $84.5 billion Fidelity Contrafund boosted its positions in Valeant and Celgene (CELG) in its latest disclosure. It began a stake in Illumina (ILMN). The $43.4 million Franklin Templeton Global
Stock Market XML and JSON Data API provided by FinancialContent Services, Inc.
Nasdaq quotes delayed at least 15 minutes, all others at least 20 minutes.
Markets are closed on certain holidays. Stock Market Holiday List
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Press Release Service provided by PRConnect.
Stock quotes supplied by Six Financial
Postage Rates Bots go here